Kirke SM, Lowder S, Lloyd JJ, Diffey BL, Matthews JN, Farr PM
First identified as a potential cognitive enhancer in 1996 by Terranova and colleagues at the French pharmaceutical development firm, Sanofi, Rimonabant was found to be of interest due to its ability to reverse the inhibition of hippocampal synaptic plasticity caused by the CBR1 agonist, WIN 55,212-2
These changes can create temporary disruption before improvement emerges
Wound Healing and Injury Recovery Protocol Dose: 2 to 3 mg per day Route: Subcutaneous (near injury site preferred) Frequency: Daily Cycle: 4 to 8 weeks or until healed Expected results: Accelerated wound closure within 2 to 3 weeks Best for: Post-surgical recovery, chronic wounds, scar reduction In animal studies, GHK-Cu collagen dressings increased collagen content 9-fold in healthy rats